featured
MGMT Promoter Methylation Testing to Predict Survival in Glioblastoma Treated With Temozolomide
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Neuro-Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
MGMT Promoter Methylation Testing to Predict Overall Survival in People With Glioblastoma Treated With Temozolomide: A Comprehensive Meta-Analysis Based on a Cochrane Systematic Review
Neuro-oncology 2021 Sep 01;23(9)1457-1469, S Brandner, A McAleenan, C Kelly, F Spiga, HY Cheng, S Dawson, L Schmidt, CL Faulkner, C Wragg, S Jefferies, JPT Higgins, KM KurianFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Brain Cancer Center of Excellence
Visit our Brain Cancer Center of Excellence for additional, in-depth coverage.